| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 11
| Issue : 5 | Page : 44-48 |
|
|
Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma
Yong Cui, Chang Dong, Bing-Qun Wu, Xin-Chun Duan, Guan Shi, Min Gong, Tian-You Wang
Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
Correspondence Address:
Dr. Chang Dong
Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Yongan Street, Xicheng District, Beijing
China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.163838
|
|
|
Background: Esophageal squamous cell carcinoma (ESCC) is a frequently occurring cancer with poor prognosis despite combined therapeutic strategies. The aim of the current study was to elucidate a further finding on the clinicopathologic significance of immunohistochemical expression of cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor (EGFR) in Chinese patients with ESCC.
Methods: Formalin-fixed paraffin-embedded surgically resected tumor samples were obtained from 140 randomly selected Chinese patients with ESCC. Sections were immunohistochemically stained for COX-2, VEGF, and EGFR. The correlations between clinicopathological features and the high expression of COX-2, VEGF, and EGFR were analyzed using the Statistical Package for the Social Sciences 19.0 software (IBM Inc., Chicago, IL, USA).
Results: In the present study, high expression of COX-2, EGFR, and VEGF was found in 64.3%, 62.1%, and 65.0%, respectively. Results showed that COX-2 overexpression was significantly correlated with degree of differentiation (P = 0.000), and lymph node metastasis (negative/positive, P = 0.002). EGFR and VEGF overexpression was significantly correlated with a differentiated degree, T stage, N stage, and tumor, node, metastases stage.
Conclusion: High expression of COX-2, EGFR, and VEGF is an unfavorable prognostic factor in ESCC, and could be used as a poor prognosis indicator for the ESCC patients. Targeting therapy to these three targets should be considered to the combined treatment in ESCC. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
